About: Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 24 February 2013

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 2013 (uk) im Februar 2013 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 24 February 2013 (en) artículu científicu espublizáu en febreru de 2013 (ast)
publication date	wds:Q59855478-BAF86426-E5ED-4C89-B081-698637335322
publication date	2013-02-24 00:00:00Z (xsd:dateTime)
author name string	wds:Q59855478-14D4E735-E871-43F7-8211-12597C94B7A7 wds:Q59855478-70B80354-481F-4209-9134-56E55044F148 wds:Q59855478-72093828-E40B-4058-A0D7-8EEF14DE4B3A wds:Q59855478-A813BFF3-486C-415A-873A-5C1D7A6DB6C8 wds:Q59855478-C98D313A-80AC-476B-B136-5000B9B26317 wds:Q59855478-CF618BD4-D826-4C06-91C8-D944EA341D62 wds:Q59855478-E730EDBC-8F0D-4230-AA88-DBC3B8BF7CDC wds:Q59855478-F7D34059-8DB0-4EB8-A5F4-5253130525B0
author name string	S Roy A M M Eggermont L Zitvogel D Lefeuvre N Chaput C Mateus E Routier J Delyon
rdfs:label	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival (en) Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival (nl)
skos:prefLabel	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival (en) Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival (nl)
name	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival (en) Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival (nl)
author	wds:Q59855478-08736E83-E7F5-4BB6-B57C-F2E0AC7E86C7 wds:Q59855478-B91493D8-7BA8-4639-B8E0-C728F71D004D
author	Caroline Robert Emilie Lanoy
title	wds:Q59855478-7C78B801-9D26-41F8-A2A2-6DA0F196FA93
title	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival (en)
page(s)	wds:Q59855478-B4B56714-1BEB-4518-9C23-7B3FD041B26F
page(s)	1697-1703
instance of	wds:Q59855478-49D5E877-F80C-4280-8F53-93A6F7FAE377
instance of	scholarly article
main subject	wds:Q59855478-D799AB6D-401E-4654-BA92-9D7497016256
main subject	metastatic melanoma
PubMed ID	wds:Q59855478-8FBCB380-500E-42F4-A762-6F23868D4DB0
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/23439861
PubMed ID	23439861
published in	wds:Q59855478-73E0F736-0318-4492-9BD5-F0C3501BE4D4
published in	Annals of Oncology
issue	wds:Q59855478-90223BFD-344F-46C4-9222-981A90AD9431
volume	wds:Q59855478-847199ED-9A7E-4528-B2DB-0B8FCE82EDB0
issue	6
volume	24
DOI	wds:Q59855478-298BBB84-40EF-4E65-BCE1-F1CA89F71F67
DOI	http://dx.doi.org/10.1093/ANNONC/MDT027
DOI	10.1093/ANNONC/MDT027
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q59855478
is cites work of	Nivolumab plus ipilimumab in advanced melanoma Clinical Development of Immune Checkpoint Inhibitors PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma Immune Checkpoint Blockade in Cancer Therapy Immune modulation in cancer with antibodies An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Mechanisms of action of therapeutic antibodies for cancer Immune modulation for cancer therapy Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab Systematic evaluation of immune regulation and modulation Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations Emerging Roles for Eosinophils in the Tumor Microenvironment Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. What have we learned from cancer immunotherapy in the last 3 years? Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma Predictive biomarkers for checkpoint inhibitor-based immunotherapy Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Monitoring immune-checkpoint blockade: response evaluation and biomarker development Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting. Emerging Biomarkers in Cutaneous Melanoma. Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors Effects of a novel Nodal-targeting monoclonal antibody in melanoma Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire Eosinophils: The unsung heroes in cancer? IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software